Hanna Rinta-Kokko1, Arto A Palmu2, Kari Auranen3, J Pekka Nuorti4, Maija Toropainen5, Lotta Siira5, Mikko J Virtanen5, Hanna Nohynek5, Jukka Jokinen6. 1. Department of Public Health Solutions, National Institute for Health and Welfare, P.O. Box 30, FI-00271 Helsinki, Finland. Electronic address: hanna.rinta-kokko@thl.fi. 2. Department of Public Health Solutions, National Institute for Health and Welfare, Biokatu 10, FI-33520 Tampere, Finland. 3. Department of Mathematics and Statistics, University of Turku, 20014 Turun yliopisto, Turku, Finland. 4. Department of Health Security, National Institute for Health and Welfare, P.O. Box 30, FI-00271 Helsinki, Finland; Department of Epidemiology, School of Health Sciences, University of Tampere, Kalevantie 4, FI-33014 Tampere, Finland. 5. Department of Health Security, National Institute for Health and Welfare, P.O. Box 30, FI-00271 Helsinki, Finland. 6. Department of Public Health Solutions, National Institute for Health and Welfare, P.O. Box 30, FI-00271 Helsinki, Finland.
Abstract
BACKGROUND: The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish National Vaccination Programme (NVP) in September 2010. The impact of PCV10 vaccination against invasive pneumococcal disease (IPD) in vaccine-eligible children has been high. We evaluated the long-term impact of PCV10 vaccination against IPD in vaccine-eligible and older, unvaccinated children six years after PCV10 introduction with a special focus on cross-protection against PCV10-related serotypes (serotypes in the same serogroups as the PCV10 types). METHODS: We used data on IPD from the national, population-based surveillance. A target cohort of vaccine-eligible children (born June 2010 or later) was followed from 3 months of age until the end of 2016. For the indirect effect, another cohort of older PCV10-ineligible children was followed from 2012 through 2016. IPD rates were compared with those of season- and age-matched reference cohorts before NVP introduction. RESULTS: Among vaccine-eligible children, the incidence of all IPD decreased by 79% (95% CI 74-83%). There was a statistically significant reduction in the incidence of 6A IPD, but for 19A, the reduction was non-significant and the incidence of 19A increased towards the end of the study period in the older vaccine-eligible children. The increase in non-PCV10 related serotypes was non-significant. In the unvaccinated older children, the incidence of all IPD decreased by 33% (95% CI 8-52%) compared to the reference cohort, and there was no impact on serotype 6A or 19A IPD. CONCLUSION: Overall, the impact of PCV10 vaccination on IPD was high in vaccine-eligible children, with a major reduction in vaccine-type disease, and without notable replacement by other serotype groups. Our data suggest that PCV10 results in long-lasting direct cross-protection against 6A IPD. For 19A, no net reduction was observed six years after NVP introduction in the vaccine-eligible cohort. The indirect impact on IPD in unvaccinated children sustained.
BACKGROUND: The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish National Vaccination Programme (NVP) in September 2010. The impact of PCV10 vaccination against invasive pneumococcal disease (IPD) in vaccine-eligible children has been high. We evaluated the long-term impact of PCV10 vaccination against IPD in vaccine-eligible and older, unvaccinated children six years after PCV10 introduction with a special focus on cross-protection against PCV10-related serotypes (serotypes in the same serogroups as the PCV10 types). METHODS: We used data on IPD from the national, population-based surveillance. A target cohort of vaccine-eligible children (born June 2010 or later) was followed from 3 months of age until the end of 2016. For the indirect effect, another cohort of older PCV10-ineligible children was followed from 2012 through 2016. IPD rates were compared with those of season- and age-matched reference cohorts before NVP introduction. RESULTS: Among vaccine-eligible children, the incidence of all IPD decreased by 79% (95% CI 74-83%). There was a statistically significant reduction in the incidence of 6A IPD, but for 19A, the reduction was non-significant and the incidence of 19A increased towards the end of the study period in the older vaccine-eligible children. The increase in non-PCV10 related serotypes was non-significant. In the unvaccinated older children, the incidence of all IPD decreased by 33% (95% CI 8-52%) compared to the reference cohort, and there was no impact on serotype 6A or 19A IPD. CONCLUSION: Overall, the impact of PCV10 vaccination on IPD was high in vaccine-eligible children, with a major reduction in vaccine-type disease, and without notable replacement by other serotype groups. Our data suggest that PCV10 results in long-lasting direct cross-protection against 6A IPD. For 19A, no net reduction was observed six years after NVP introduction in the vaccine-eligible cohort. The indirect impact on IPD in unvaccinated children sustained.
Authors: Ana Paula Cassiolato; Samanta Cristine Grassi Almeida; Ana Lúcia Andrade; Ruth Minamisava; Maria Cristina de Cunto Brandileone Journal: PLoS One Date: 2018-11-29 Impact factor: 3.240
Authors: Laura L Hammitt; Anthony O Etyang; Susan C Morpeth; John Ojal; Alex Mutuku; Neema Mturi; Jennifer C Moisi; Ifedayo M Adetifa; Angela Karani; Donald O Akech; Mark Otiende; Tahreni Bwanaali; Jackline Wafula; Christine Mataza; Edward Mumbo; Collins Tabu; Maria Deloria Knoll; Evasius Bauni; Kevin Marsh; Thomas N Williams; Tatu Kamau; Shahnaaz K Sharif; Orin S Levine; J Anthony G Scott Journal: Lancet Date: 2019-04-15 Impact factor: 79.321
Authors: Eleanor F G Neal; Stefan Flasche; Cattram D Nguyen; F Tupou Ratu; Eileen M Dunne; Lanieta Koyamaibole; Rita Reyburn; Eric Rafai; Mike Kama; Belinda D Ortika; Laura K Boelsen; Joseph Kado; Lisi Tikoduadua; Rachel Devi; Evelyn Tuivaga; Catherine Satzke; E Kim Mulholland; W John Edmunds; Fiona M Russell Journal: Vaccine Date: 2019-10-23 Impact factor: 3.641
Authors: Todd D Swarthout; Ana Ibarz-Pavon; Gift Kawalazira; George Sinjani; James Chirombo; Andrea Gori; Peter Chalusa; Farouck Bonomali; Roseline Nyirenda; Edwin Bulla; Comfort Brown; Jacquline Msefula; Marjory Banda; Jean Kachala; Charles Mwansambo; Marc Yr Henrion; Stephen B Gordon; Neil French; Robert S Heyderman Journal: BMJ Open Date: 2021-06-17 Impact factor: 2.692